1
|
Ramkumar S, Sivanandham S. The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma. Cureus 2021; 13:e20339. [PMID: 34934597 PMCID: PMC8668044 DOI: 10.7759/cureus.20339] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/10/2021] [Indexed: 12/03/2022] Open
Abstract
Newer diagnostic modalities have revolutionized the pathologist’s approach to diagnosing thyroid malignancies. Molecular characterization of these malignancies has helped circumvent common morphologic diagnostic difficulties by integrating their genotypic, phenotypic, and immunohistochemical features. BRAF V600E mutation has been characterized as highly specific for thyroid carcinoma, especially papillary thyroid carcinoma (PTC); human bone marrow endothelial marker-1 (HBME-1) and galectin-3 are also such markers that are highly specific for PTC. We propose to study HBME-1 and galectin-3 expression and BRAF V600E mutation in thyroid neoplasms and do a comparative analysis to determine whether there is a correlation between BRAF V600E expression and that of HBME-1 and galectin-3. We further propose to analyze the individual and combined diagnosed utility of the above-mentioned ancillary diagnostic techniques.
Collapse
|
2
|
Yi N, Zhao X, Ji J, Xu M, Jiao Y, Qian T, Zhu S, Jiang F, Chen J, Xiao M. Serum galectin-3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer. J Cell Mol Med 2020; 24:11583-11591. [PMID: 32886424 PMCID: PMC7576229 DOI: 10.1111/jcmm.15775] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 08/01/2020] [Accepted: 08/05/2020] [Indexed: 12/25/2022] Open
Abstract
Galectin‐3 plays an important role in cell‐cell adhesion, macrophage activation, angiogenesis, metastasis and apoptosis and is overexpressed in pancreatic cancer. We explored the importance of galectin‐3 in the screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer. A time‐resolved fluorescence immunoassay was performed to detect serum galectin‐3 level. Serum samples were collected from healthy controls and patients with pancreatic cancer before and after different treatments, and the relationships between galectin‐3 level and clinical parameters were analysed. Among the healthy controls, one individual with an abnormally high concentration of galectin‐3 (9.85 μg/L) was diagnosed with pancreatic cancer. Compared to the pre‐operative level, galectin‐3 concentration significantly decreased in patients with radical excision 1 month after surgery (P < .05), but showed no obvious change in patients who underwent palliative resection. Additionally, among patients with radical excision, carcinoma recurrence rate was significantly higher in those with increased or unchanged galectin‐3 level. Retrospective analysis revealed the extraordinarily high value and high specificity of galectin‐3 for predicting 3‐year survival (P < .001). Thus, galectin‐3 may serve as a potential biomarker for the screening and early diagnosis of pancreatic cancer and as an independent prognostic indicator in patients with pancreatic cancer.
Collapse
Affiliation(s)
- Nan Yi
- Department of Gastroenterology, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China
| | - Xuying Zhao
- Department of Endocrinology, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China
| | - Jie Ji
- Department of Gastroenterology, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China.,Medical College, Nantong University, Nantong, China
| | - Minxue Xu
- Department of Gastroenterology, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China.,Medical College, Nantong University, Nantong, China
| | - Yujie Jiao
- Department of Gastroenterology, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China.,Medical College, Nantong University, Nantong, China
| | - Tianyang Qian
- Chinese Medicine 193, First Clinical Medical School, Nanjing University of Chinese Medicine, Nanjing, China
| | - Shengze Zhu
- Medical College, Nantong University, Nantong, China
| | - Feng Jiang
- Department of Gastroenterology, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China
| | - Jianhua Chen
- Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.,Tongji University Cancer Center, Shanghai, China.,Department of Oncology, Shanghai Dermatology Hospital, Tongji University, Shanghai, China
| | - Mingbing Xiao
- Department of Gastroenterology, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China
| |
Collapse
|
3
|
Wang H, Yan X, Zhang H, Zhan X. CircRNA circ_0067934 Overexpression Correlates with Poor Prognosis and Promotes Thyroid Carcinoma Progression. Med Sci Monit 2019; 25:1342-1349. [PMID: 30779728 PMCID: PMC6390454 DOI: 10.12659/msm.913463] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Circular RNAs are important regulators in human cancers, including thyroid carcinoma. The circ_0067934 RNA is reported to participate in hepatocellular carcinoma, esophageal squamous cell carcinoma, and lung cancer. Whether it regulates thyroid carcinoma remains unclear. The purpose of this study was to research potential mechanisms of circ_0067934 in thyroid tumors to provide potential new diagnostic and treatment targets. MATERIAL AND METHODS The expression level of circ_0067934 in thyroid tumors, adjacent tissues, and cell lines was measured by qRT-PCR. The Kaplan-Meier survival curve analysis was used to explore the relationship between circ_0067934 level and survival time of patients. Circ_0067934 was knocked down to research its functional role in thyroid tumors. Cell proliferation was detected by CCK-8 (cell counting kit-8) assay. Migration and invasion were analyzed by Transwell assay. Western blot was applied to analyze the expression of epithelial-mesenchymal-transition (EMT) and PI3K/AKT related proteins. RESULTS Compared with adjacent tissue, circ_0067934 was highly expressed in thyroid tumors. Circ_0067934 expression level was highly expressed in thyroid tumor cell lines. Patients with high expression of circ_0067934 showed lower survival rates. Knockdown of circ_0067934 inhibited cell proliferation, migration, and invasion and also promoted apoptosis. In addition, circ_0067934 knockdown inhibited EMT and PI3K/AKT signaling pathways. CONCLUSIONS circ_0067934 could improve the development of thyroid carcinoma by promoting EMT and PI3K/AKT signaling pathways.
Collapse
Affiliation(s)
- Huihui Wang
- Department of Endocrinology, Qiqihar First Hospital, Qiqihar, Heilongjiang, China (mainland)
| | - Xiaoguang Yan
- Department of Endocrinology, Qiqihar First Hospital, Qiqihar, Heilongjiang, China (mainland)
| | - Haijun Zhang
- Department of Endocrinology, Qiqihar First Hospital, Qiqihar, Heilongjiang, China (mainland)
| | - Xiaorong Zhan
- Department of Endocrinology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland)
| |
Collapse
|
4
|
Mohamad Pakarul Razy NH, Wan Abdul Rahman WF, Win TT. Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study. Asian Pac J Cancer Prev 2019; 20:277-282. [PMID: 30678450 PMCID: PMC6485559 DOI: 10.31557/apjcp.2019.20.1.277] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Introduction: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays an important role in thyroid cancer. VEGF is known to have high affinity to VEGF receptors such as VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and studies showed the increasing incidence of PTC arising in nodular hyperplasia. Targeted therapy on these growth factors and receptors are used in management of both differentiated and undifferentiated thyroid carcinoma. This study aims to determine the expression of VEGF and VEGF receptors (VEGFR) in thyroid nodular hyperplasia and PTC. Methods: A cross-sectional study based on paraffinized archival tissue blocks of 113 nodular hyperplasias and 67 PTC from the thyroidectomy specimens in the year of 2003 to 2014. The tissue sections were then stained by immunohistochemistry for VEGF, VEGFR-1 and VEGFR-2. The lymph node involvement and extrathyroid extension also were determined. Results: The mean age of PTC patients was 44.7±15.8 years and nodular hyperplasia were 42.2±13.6 years. There was a statistical difference of VEGFR-1 (p=0.028) and VEGFR-2 (p=0.003) expression between nodular hyperplasia and PTC. However, no significant difference of VEGF expression (p=0.576) between both diseases. Co-expression of VEGF and VEGFR-1 was significant in both nodular hyperplasia (p=0.016) and PTC (p=0.03), meanwhile no relevant relationship for VEGF and VEGFR-2 expression (p>0.05). No significant association (p>0.05) between lymph node status and extrathyroid extension with age groups, gender, VEGF and VEGFR expression. Conclusions: VEGF, VEGFR-1 and VEGFR-2 showed overexpression in both nodular hyperplasia and PTC. The expression of VEGFR-1 and VEGFR-2 are more significant in PTC with relevant co-expression of VEGF and VEGFR-1. Therefore, the inhibition of VEGFR offers a promising prospect for tumour management in thyroid carcinoma.
Collapse
|
5
|
Wu KL, Kuo CM, Huang EY, Pan HM, Huang CC, Chen YF, Hsiao CC, Yang KD. Extracellular galectin-3 facilitates colon cancer cell migration and is related to the epidermal growth factor receptor. Am J Transl Res 2018; 10:2402-2412. [PMID: 30210679 PMCID: PMC6129507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Accepted: 07/11/2018] [Indexed: 06/08/2023]
Abstract
We previously found that galectin-3 enhanced DLD-1 cell migration through the K-Ras-Raf-Erk1/2 pathway, but the effect of extracellular galectin-3 on cancer cell migration and its interaction with the epidermal growth factor receptor (EGFR) remained unknown. We aimed to determine the effect of extracellular galectin-3 on colon cancer cell migration and its correlation with the EGFR expression. Western blotting was performed to analyze galectin-3 secretion, shRNA was used to stably knock down galectin-3 expression and a migration assay was performed to evaluate colon cancer cell migration. Tissues from eighty patients with four different stages of colon cancer were obtained and compared to normal colon tissue. The galectin-3 knockdown colon cancer cells exhibited decreased migration, which was restored by recombinant galectin-3. An EGFR blocking antibody decreased colon cancer cell migration. The addition of recombinant galectin-3 increased phosphorylated EGFR expression within minutes and enhanced the internalization of the EGFR from the cell membrane to the cytoplasm, particularly upon EGF stimulation. Extracellular galectin-3 increased colon cancer cell migration, which correlated with the EGFR. Targeting galectin-3 may have a synergistic effect on EGFR-targeted therapy.
Collapse
Affiliation(s)
- Keng-Liang Wu
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial HospitalNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung UniversityNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
| | - Chung-Mou Kuo
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial HospitalNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
| | - Eng-Yen Huang
- Department of Radiation Oncology, Kaohsiung Chang Gung Memorial HospitalNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung UniversityNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
| | - Hui-Mei Pan
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial HospitalNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
| | - Chao-Cheng Huang
- Department of Pathology, Kaohsiung Chang Gung Memorial HospitalNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
| | - Yi-Fan Chen
- Department of Radiation Oncology, Kaohsiung Chang Gung Memorial HospitalNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
| | - Chang-Chun Hsiao
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung UniversityNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
- Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial HospitalNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
| | - Kuender D Yang
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung UniversityNo. 123, Ta-Pei Road, Niao Song Dist, Kaohsiung 83301, Taiwan
- Institute of Clinical Medicine, National Yang Ming UniversityNo. 155, Sec. 2, Linong Street, Taipei 112, Taiwan
- Department of Medical Research, Mackay Memorial Hospital, Institute of Biomedical Sciences, Mackay Medical SchoolNo. 46, Sec. 3, Zhongzheng Road, Sanzhi Dist, New Taipei 252, Taiwan
| |
Collapse
|
6
|
Huang L, Wang X, Huang X, Gui H, Li Y, Chen Q, Liu D, Liu L. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett 2018. [PMID: 29541194 PMCID: PMC5835856 DOI: 10.3892/ol.2018.7873] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The aim of the present study was to examine the rate of BRAF mutation and the expression profiles of CK19, galectin-3, CD56, thyroid peroxidase (TPO) and Ki67 in papillary thyroid carcinoma (PTC) and papillary thyroid micro-carcinoma (PTMC). A total of 246 cases of thyroid disease were collected, including PTC, PTMC, nodular goiter (NG) and Hashimoto thyroiditis (HT). The results revealed that CK19 expression was 116/120 in PTC, 61/64 in PTMC, 2/34 in NG and 1/28 in HT. Galectin-3 positive expression was 115/120 in PTC, 60/64 in PTMC, 6/34 in NG and 4/28 in HT. TPO positive expression was 8/120 in PTC, 1/64 in PTMC, 30/34 in NG and 25/28 in HT. CD56-positive expression was 12/120 in PTC, 3/64 in PTMC, 33/34 in NG and 26/28 in HT. Ki67 labeling index was 2.52±0.46% in PTC (120 cases), 2.62±0.52% in PTMC (64 cases), 2.55±0.44% in NG (34 cases) and 2.58±0.48% in HT (28 cases). BRAF mutation rate was 93/120 in PTC, 47/64 in PTMC, 3/34 in NG and 2/28 in HT. These results suggested that expression patterns of CK19, galectin-3, CD56 and TPO and BRAF mutation exhibit diagnosis value in thyroid disease. However, Ki67-positive rate exhibits no notable diagnosis value in thyroid disease.
Collapse
Affiliation(s)
- Lihua Huang
- Department of Pathology, Wuhan Puai Hospital, Wuhan, Hubei 430030, P.R. China
| | - Xuming Wang
- Department of Histopathology, Jiangda Pathology Institute, Jianghan University, Wuhan, Hubei 430056, P.R. China.,Department of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China
| | - Xuan Huang
- Department of Histopathology, Jiangda Pathology Institute, Jianghan University, Wuhan, Hubei 430056, P.R. China.,Department of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China
| | - Huawei Gui
- Department of Pathology, Wuhan Puai Hospital, Wuhan, Hubei 430030, P.R. China
| | - Yan Li
- Department of Histopathology, Jiangda Pathology Institute, Jianghan University, Wuhan, Hubei 430056, P.R. China.,Department of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China
| | - Qiongxia Chen
- Department of Histopathology, Jiangda Pathology Institute, Jianghan University, Wuhan, Hubei 430056, P.R. China.,Department of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China
| | - Dongling Liu
- Department of Pathology, Wuhan Puai Hospital, Wuhan, Hubei 430030, P.R. China
| | - Lijiang Liu
- Department of Histopathology, Jiangda Pathology Institute, Jianghan University, Wuhan, Hubei 430056, P.R. China.,Department of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China
| |
Collapse
|
7
|
Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017; 18:ijms18081756. [PMID: 28800068 PMCID: PMC5578146 DOI: 10.3390/ijms18081756] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2017] [Revised: 08/08/2017] [Accepted: 08/10/2017] [Indexed: 02/07/2023] Open
Abstract
The literature on Galectin-3 (Gal-3) was systematically reviewed to achieve more robust information on its histologic reliability in identifying thyroid cancers and on the concordance between Gal-3 test in histologic and cytologic samples. A computer search of the PubMed and Scopus databases was conducted by combinations of the terms thyroid and Gal-3. Initially, 545 articles were found and, after their critical review, 52 original papers were finally included. They reported 8172 nodules with histologic evaluation of Gal-3, of which 358 with also preoperative FNAC Gal-3 assessment. At histology, Gal-3 sensitivity was 87% (95% confidence intervals [CI] from 86% to 88%), and specificity 87% (95% CI from 86% to 88%); in both cases, we found heterogeneity (I2 85% and 93%, respectively) and significant publication bias (p < 0.001). The pooled rate of positive Gal-3 at fine needle aspiration (FNAC) among cancers with histologically proven Gal-3 positivity was 94% (95% CI from 89% to 97%), with neither heterogeneity (I2 14.5%) nor bias (p = 0.086). These data show high reliability of Gal-3 for thyroid cancer at histology, while its sensitivity on FNAC samples is lower. The limits of cytologic preparations and interpretation of Gal-3 results have to be solved.
Collapse
|
8
|
Xin Y, Guan D, Meng K, Lv Z, Chen B. Diagnostic accuracy of CK-19, Galectin-3 and HBME-1 on papillary thyroid carcinoma: a meta-analysis. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2017; 10:8130-8140. [PMID: 31966665 PMCID: PMC6965469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Accepted: 05/20/2017] [Indexed: 06/10/2023]
Abstract
The study aimed at evaluating the diagnostic accuracy of cytokeratin 19 (CK-19), Galectin-3 and hector battifora mesothelial antigen-1 (HBME-1) for papillary thyroid carcinoma (PTC). The eligible studies were searched in relevant databases with predefined key searching terms and inclusion criteria. Then, the quality assessment was performed by using Diagnostic Accuracy Studies scoring tool. Following the heterogeneity test, a meta-analysis of pooled several effect size including sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) with their 95% confidence intervals (CIs) were conducted by Meta-DiSc software. Next, the summary receiver operating characteristic ROC (SROC) curve was drawn. Total 29 studies with high quality were included in this meta-analysis. The pooled result of CK-19 showed that sensitivity, specificity, PLR, NLR and DOR were 0.816 (95% CI: 0.799-0.832), 0.872 (95% CI: 0.855-0.888), 5.900 (95% CI: 5.193-6.703), 0.205 (95% CI: 0.185-0.228), respectively. For Galectin-3, the pooled sensitivity, specificity, PLR, NLR and DOR were 0.842 (95% CI: 0.825-0.858), 0.833 (95% CI: 0.814-0.851), 5.057 (95% CI: 4.494-5.690), 0.176 (95% CI: 0.154-0.200) and 33.312 (95% CI: 26.403-42.029). For HBME-1, the pooled sensitivity, specificity, PLR, NLR and DOR were 0.928 (95% CI: 0.913-0.941), 0.864 (95% CI: 0.847-0.880), 6.204 (95% CI: 5.498-7.002), 0.082 (95% CI: 0.067-0.102), 57.107 (95% CI: 43.421-75.107), respectively. The area under curve (AUC) value in SROC curve of CK-19, Galectin-3 and HBME-1 were 0.9134 (95% CI: 0.877-0.950), 0.8452 (95% CI: 0.809-0.882) and 0.9047 (95% CI: 0.868-0.941), respectively. Compared with CK-19 and Galectin-3, HBME-1 was a more accurate maker and might be used independently for PTC diagnosis. CK-19 and Galectin-3 might as second-line detection for PTC diagnosis.
Collapse
Affiliation(s)
- Ying Xin
- Department of Thyroid & Breast Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeHangzhou 310014, Zhejiang, China
| | - Dandan Guan
- Department of Thyroid & Breast Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeHangzhou 310014, Zhejiang, China
| | - Kexin Meng
- Department of Thyroid & Breast Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeHangzhou 310014, Zhejiang, China
| | - Zhenye Lv
- Department of Thyroid & Breast Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeHangzhou 310014, Zhejiang, China
| | - Bin Chen
- Department of Hepatopancreatobiliary Surgery, The Affiliated Hangzhou Hospital of Nanjing Medical UniversityHangzhou 310006, Zhejiang, China
- Department of Hepatopancreatobiliary Surgery, The Affiliated Hospital of Hangzhou Normal UniversityHangzhou 310015, Zhejiang, China
| |
Collapse
|
9
|
Noroozinia F, Gheibi A, Ilkhanizadeh B, Abbasi A. CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN. ACTA ENDOCRINOLOGICA-BUCHAREST 2016; 12:387-391. [PMID: 31149120 DOI: 10.4183/aeb.2016.387] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Context Thyroid cancer is the most common endocrine malignancy. Within various subtypes of thyroid neoplasms, those with follicular growth pattern usually make diagnostic problems. Objective To examine ck19 expression as a diagnostic marker in thyroid neoplasms with follicular growth pattern. Design In this cross sectional study, 86 patients were enrolled. Subjects and Methods Totally 22 follicular adenoma (FA), 18 well differentiated tumors with undetermined malignant potential (WT-UMP) and 46 follicular variants of papillary thyroid carcinoma (FV-PTC) were enrolled and examined for Ck19 expression by immunohistochemistry staining. Membranous/cytoplasmic staining patterns were considered as positive. Specimens without staining were considered as 0, < 5% positively stained cells as 1+, 5%-25% as 2+, 25%-75% as 3+ and >75% as 4+. Result CK19 was negative in most cases of FA while positive in most WDT-UMP and FV-PTCs, p<0.001. Additionally, most cases with 2+ and 3+ staining patterns were FV-PTC (75% and 81%, respectively, p<0.001) and none of FAs showed 3+ positivity (p<0.001). Additionally, most of strongly positive results in patients > 45 y/o were PTC (p<0.001). Conclusion Ck19 is a useful marker in differentiating FA from FV-PTC. We found diffuse and strong (3+) staining pattern in FV-PTC but none of FAs were so. We concluded that diffuse and strong staining for ck19 in a thyroid lesion with follicular pattern of growth, especially in a patient older than 45 y/o should raise the possibility of malignancy.
Collapse
Affiliation(s)
- F Noroozinia
- Urmia University of Medical Sciences, Department of Pathology, Urmia, Iran
| | - A Gheibi
- Urmia University of Medical Sciences, Department of Pathology, Urmia, Iran
| | - B Ilkhanizadeh
- Urmia University of Medical Sciences, Department of Pathology, Urmia, Iran
| | - A Abbasi
- Urmia University of Medical Sciences, Department of Pathology, Urmia, Iran
| |
Collapse
|
10
|
Tang W, Huang C, Tang C, Xu J, Wang H. Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis. Onco Targets Ther 2016; 9:455-60. [PMID: 26858526 PMCID: PMC4730995 DOI: 10.2147/ott.s94514] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Background Galectin-3 is a member of the beta-galactoside-binding protein family and functions as a modulator of cell growth through galactoside-binding protein correlated with the occurrence and metastasis of papillary thyroid carcinoma (PTC). Methods A systematic review of published articles on Web of Science and PubMed was performed. After establishing inclusion and exclusion criteria, nine articles were selected. Three studies referred to galectin-3 expression in PTC and non-PTC patients. Three studies referred to galectin-3 expression in PTC patients with lymph node metastasis (LNM) and without LNM. Three studies referred to galectin-3 expression in both PTC (with and without LNM) and non-PTC patients. Data analysis was performed by using RevMan5.2 software. Results A total of 424 patients from six eligible studies that provided data about galectin-3 expression in PTC and non-PTC patients were included. A total of 378 patients from six eligible studies that provided data about galectin-3 expression in PTC with LNM and without LNM were included. Immunohistochemistry technique was used in all the studies. Galectin-3 was found to be a highly sensitive (275/424, 64.86%) marker in the diagnosis of PTC, but was found to be expressed only in a few cases involving other types of thyroid lesions (58/424, 13.68%). The odds ratio, expressed as PTC group versus other thyroid lesions group, was 13.97 (95% CI: 7.51–26.01, P<0.00001). The results also showed that the positive expression rates of galectin-3 in PTC patients with LNM were higher than those in PTC patients without LNM. Conclusion This meta-analysis demonstrated that galectin-3 may become a potentially useful immunomarker to distinguish between PTC and non-PTC patients. In addition, PTC patients with positive expression of galectin-3 were more prone to LNM.
Collapse
Affiliation(s)
- Weiwei Tang
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China
| | - Congwei Huang
- Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China
| | - Chongyin Tang
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China
| | - Jin Xu
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China
| | - Hanjin Wang
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China
| |
Collapse
|
11
|
Zhang H, Teng X, Liu Z, Zhang L, Liu Z. Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2015; 34:16. [PMID: 25887589 PMCID: PMC4349308 DOI: 10.1186/s13046-015-0132-y] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/12/2014] [Accepted: 02/02/2015] [Indexed: 11/30/2022]
Abstract
Background To detect genetic expression profile alterations after papillary thyroid carcinoma (PTC) cells transfected with chemokine receptor CXCR7 gene by gene microarray, and gain insights into molecular mechanisms of how CXCR7 regulating PTC growth and metastasis. Methods The Human OneArray microarray was used for a complete genome-wide transcript profiling of CXCR7 transfected PTCs (K1-CXCR7 cells), defined as experimental group. Non CXCR7 transfected PTCs (K1 cells) were used as control group. Differential analysis for per gene was performed with a random variance model and t test, p values were adjusted to control the false discovery rate. Gene ontology (GO) on differentially expressed genes to identify the biological processes in modulating the progression of papillary thyroid carcinoma. Pathway analysis was used to evaluate the signaling pathway that differentially expressed genes were involved in. In addition, quantitative real-time polymerase chain reaction (q-PCR) and Western blot were used to verify the top differentially expression genes. Results Comparative analysis revealed that the expression level of 1149 genes was changed in response to CXCR7 transfection. After unsupervised hierarchical clustering analysis, 270 differentially expressed genes were filtered, of them 156 genes were up-regulated whereas 114 genes were down-regulated in K1-CXCR7 cells. GO enrichment analysis revealed the differentially expressed genes were mainly involved in biopolymer metabolic process, signal transduction and protein metabolism. Pathway enrichment analysis revealed differentially expressed genes were mainly involved in ECM-receptor interaction, Focal adhesion, MAPK signaling pathway and Cytokine-cytokine receptor interaction pathway. More importantly, the expression level of genes closely associated with tumor growth and metastasis was altered significantly in K1-CXCR7 cells, including up-regulated genes FN1, COL1A1, COL4A1, PDGFRB, LTB, CXCL12, MMP-11, MT1-MMP and down-regulated genes ITGA7, and Notch-1. Conclusions Gene expression profiling analysis of papillary thyroid carcinoma can further delineate the mechanistic insights on how CXCR7 regulating papillary thyroid carcinoma growth and metastasis. CXCR7 may regulate growth and metastasis of papillary thyroid carcinoma via the activation of PI3K/AKT pathway and its downstream NF-κB signaling, as well as the down-regulation of Notch signaling.
Collapse
Affiliation(s)
- Hengwei Zhang
- Department General Surgery, Affiliated Shenjing Hospital, China Medical University, No.36 Sanhao Street, Shenyang, 110004, China.
| | - Xuyong Teng
- Department General Surgery, Affiliated Shenjing Hospital, China Medical University, No.36 Sanhao Street, Shenyang, 110004, China.
| | - Zhangyi Liu
- Department General Surgery, Affiliated Shenjing Hospital, China Medical University, No.36 Sanhao Street, Shenyang, 110004, China.
| | - Lei Zhang
- Department General Surgery, Affiliated Shenjing Hospital, China Medical University, No.36 Sanhao Street, Shenyang, 110004, China.
| | - Zhen Liu
- Department General Surgery, Affiliated Shenjing Hospital, China Medical University, No.36 Sanhao Street, Shenyang, 110004, China.
| |
Collapse
|
12
|
Huang C, Cai Z, Huang M, Mao C, Zhang Q, Lin Y, Zhang X, Tang B, Chen Y, Wang X, Qian Z, Ye L, Peng Y, Xu H. miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α. J Clin Endocrinol Metab 2015; 100:E204-13. [PMID: 25423566 PMCID: PMC4318892 DOI: 10.1210/jc.2014-2883] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. It has been demonstrated that micro-RNAs (miRNAs) are involved in the development of PTC. The miRNA-chromatin immunoprecipitation microarray assay revealed down-regulation of miR-219-5p; however, the effect of miR-219-5p on PTC cell growth remains unknown. This result implied the critical role of miR-219-5p in the development of PTC. METHODS We investigated the association between miR-219-5p and PTC development. Expression of miR-219-5p was monitored in 30 PTC tissue specimens and compared with that in 30 normal thyroid tissue specimens. The effect of miR-219-5p on PTC development was studied by cell proliferation, migration, and apoptosis assays. The underlying mechanism was clarified by a reporter assay and rescue experiment. RESULTS The current study confirmed that miR-219-5p expression was inhibited in PTC tissue samples. There were statistically significant differences in the expression of miR-219-5p with regard to sex, tumor size, and lymph node metastasis in patients with PTC. Forced expression of miR-219-5p suppressed PTC cell proliferation and migration and promoted apoptosis. Further study showed that estrogen receptor (ER) α was the direct target of miR-219-5p and mediated the effect of miR-219-5p on PTC occurrence. Expression of miR-219-5p was inversely correlated with that of ERα. Importantly, ERα overexpression in PTC cells rescued the inhibitory effect of miR-219-5p on PTC cell proliferation and migration. Thus, our results indicated that miR-219-5p played a critical role in PTC growth by inhibiting ERα. CONCLUSION Our investigation identified miR-219-5p as a negative regulator of PTC development through targeting of ERα.
Collapse
Affiliation(s)
- Chen Huang
- Department of Endocrinology and Metabolism and Department of General Surgery (C.H., Y.L. Y.P., H.X.), Shanghai Jiaotong University Affiliated First People's Hospital, Shanghai 200080, China; Department of Endocrinology and Metabolism (Z.C., X.Z., B.T., Y.C., X.W., Z.Q., H.X.), Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China; Department of Medical Oncology (Q.Z.), Fudan University Shanghai Cancer Center (M.H.); Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Nuclear Medicine or Institute of Oncology (C.M.), The Hospital Affiliated to Jiangsu University, Zhenjiang 212001, China; Department of Urology (Q.Z.), Shanghai Traditional Chinese and Medicine Integrated Hospital, Shanghai 200082, China; and Department of Endocrinology and Metabolism (L.Y.), Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|